EYLEA® (aflibercept) Injection 2 mg (0.05mL)

BIOLOGICAL4 trials

Sponsors

Unity Biotechnology, Inc., 4D Molecular Therapeutics, AiViva BioPharma, Inc.

Conditions

Macular Neovascularization Secondary to Age-Related Macular DegenerationNeovascular (Wet) Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-related Macular Degeneration

Phase 2

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

CompletedNCT05275205

Unity Biotechnology, Inc.Neovascular Age-related Macular Degeneration

Start: 2022-03-02End: 2023-07-25Updated: 2024-08-07

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Not yet recruitingNCT07557121

AiViva BioPharma, Inc.Neovascular (Wet) Age-Related Macular Degeneration

Start: 2026-07-01End: 2027-08-23Target: 35Updated: 2026-04-29

Phase 3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Active, not recruitingNCT06864988

4D Molecular TherapeuticsMacular Neovascularization Secondary to Age-Related Macular Degeneration

Start: 2025-03-03End: 2028-06-01Target: 480Updated: 2026-06-01

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

RecruitingNCT07064759

4D Molecular TherapeuticsNeovascular Age-Related Macular Degeneration (nAMD)

Start: 2025-07-22End: 2029-02-01Target: 480Updated: 2026-04-16